HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prolacta Formula Fortifier Starts Trial For Newborns With Rare Heart Condition

This article was originally published in The Rose Sheet

Executive Summary

Prolacta Bioscience developed human milk-based formula fortifier for full-term infants born with conditions that make them vulnerable to nutrition deficiencies. Pending results from research at 12 US hospitals, the product would roll out commercially in 2018.

You may also be interested in...



Updated Infant Formula Regs Raise Quality Control Bar

Beginning in July 2014 manufacturers must test infant formulas for salmonella and cronobacter before distribution, according to an IFR and guidances FDA released Feb. 6. The rule also requires firms to prove formula meets quality standards including providing all necessary nutrients and appropriate levels of protein.

IFF’s New CEO: Commercial Execution Strategy Will Get Biz Back On Track

Under CEO Erik Fyrwald, IFF is committed to improving commercial execution across its four businesses after five years of overall underperformance.

Coty Continues Licensing Spree With Etro; CEO Nabi Shares Prestige Fragrance Vision

At CAGNY 2024, CEO Sue Nabi discussed Coty’s prestige fragrance strategy, including growing emphasis on ultra-premium offerings and continued focus on fashion-driven licenses, the same day the company announced a long-term fragrance licensing deal with Italian brand Etro.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS109104

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel